Request Demo
Last update 23 Mar 2025
Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
Last update 23 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms 610 anti-IL5 antibody, Recombinant anti-IL-5 humanized monoclonal antibody, 610 + [1] |
Target |
Action inhibitors |
Mechanism IL-5 inhibitors(Interleukin-5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
11
Clinical Trials associated with Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)CTR20244205
一项评价610治疗成人哮喘受试者的有效性和安全性的多中心、随机、双盲、安慰剂对照IIb期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase IIb clinical trial to evaluate the efficacy and safety of 610 in the treatment of adult asthma subjects
NCT06680947
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb, Effcacy and Safety Study of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy in Adult Subjects With Severe Asthma
CTR20241581
一项评价610治疗成人哮喘受试者的有效性和安全性的多中心、随机、双盲、安慰剂对照Ⅲ期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of 610 in the treatment of adult asthma subjects
100 Clinical Results associated with Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
Login to view more data
6
Literatures (Medical) associated with Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)01 Feb 2023Laryngo- rhino- otologie
Empfehlungen zur Überprüfung der Wirksamkeit und Verlaufsdokumentation von Mepolizumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC)
Article
Author: Casper, I. ; Hoffmann, A. S. ; Zuberbier, J. ; Welkoborsky, H. J. ; Beule, A. G. ; Hildenbrand, T. ; Hintschich, C. A. ; Förster-Ruhrmann, U. ; Guntinas-Lichius, O. ; Hagemann, J. ; Pfaar, O. ; Chaker, A. M. ; Deitmer, T. ; Schlenter, W. ; Stöver, T. ; Strieth, S. ; Beutner, C. ; Rudack, C. ; Hoffmann, T. K. ; Dazert, S. ; Olze, H. ; Klimek, F. ; Werminghaus, P. ; Klimek, L. ; Cuevas, M. ; Bachert, C. ; Gröger, M. ; Gosepath, J. ; Bärhold, F. ; Becker, S. ; Huppertz, T. ; Wrede, H. ; Bergmann, C. ; Wollenberg, B. ; Laudien, M. ; Weber, R. K.
01 Apr 2022Laryngo- rhino- otologieQ4 · MEDICINE
Positionspapier: Empfehlungen zur Anwendung von Mepolizumab bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC)
Q4 · MEDICINE
Article
Author: Welkoborsky, H. J. ; Beule, A. G. ; Hintschich, C. A. ; Guntinas-Lichius, O. ; Förster-Ruhrmann, U. ; Hagemann, J. ; Bachert, C. ; Deitmer, T. ; Chaker, A. M. ; Schlenter, W. ; Stöver, T. ; Strieth, S. ; Hoffmann, T. K. ; Olze, H. ; Zuberbier, J. ; Dazert, S. ; Klimek, F. ; Klimek, L. ; Cuevas, M. ; Becker, S. ; Huppertz, T. ; Bergmann, C. ; Wrede, H. ; Wollenberg, B. ; Rudack, C.
03 Jul 2017Expert opinion on biological therapyQ3 · MEDICINE
Q3 · MEDICINE
Review
Author: Antoniu, Sabina Antonela
100 Deals associated with Recombinant anti-IL-5 humanized monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Asthma | Phase 3 | - | 01 Apr 2024 | |
| Eosinophilic Asthma | Phase 3 | - | 01 Apr 2024 | |
| Autoimmune Diseases | Phase 1 | China | 30 Jan 2022 | |
| Severe asthma | Phase 1 | China | 06 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free